Perrigo (PRGO) Competitors $21.66 -0.27 (-1.23%) As of 03:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PRGO vs. JAZZ, CORT, SUPN, NKTR, PCRX, OMER, ASMB, CPIX, LLY, and JNJShould you be buying Perrigo stock or one of its competitors? The main competitors of Perrigo include Jazz Pharmaceuticals (JAZZ), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Omeros (OMER), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), and Johnson & Johnson (JNJ). These companies are all part of the "pharmaceuticals" industry. Perrigo vs. Its Competitors Jazz Pharmaceuticals Corcept Therapeutics Supernus Pharmaceuticals Nektar Therapeutics Pacira BioSciences Omeros Assembly Biosciences Cumberland Pharmaceuticals Eli Lilly and Company Johnson & Johnson Jazz Pharmaceuticals (NASDAQ:JAZZ) and Perrigo (NYSE:PRGO) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership. Which has higher earnings & valuation, JAZZ or PRGO? Jazz Pharmaceuticals has higher earnings, but lower revenue than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJazz Pharmaceuticals$4.07B2.06$560.12M-$6.73-20.50Perrigo$4.33B0.69-$171.80M-$0.58-37.34 Do institutionals & insiders have more ownership in JAZZ or PRGO? 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.9% of Perrigo shares are owned by institutional investors. 4.3% of Jazz Pharmaceuticals shares are owned by insiders. Comparatively, 0.4% of Perrigo shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media prefer JAZZ or PRGO? In the previous week, Jazz Pharmaceuticals had 1 more articles in the media than Perrigo. MarketBeat recorded 6 mentions for Jazz Pharmaceuticals and 5 mentions for Perrigo. Jazz Pharmaceuticals' average media sentiment score of 1.32 beat Perrigo's score of 0.51 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jazz Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Perrigo 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is JAZZ or PRGO more profitable? Perrigo has a net margin of -1.86% compared to Jazz Pharmaceuticals' net margin of -9.91%. Perrigo's return on equity of 9.09% beat Jazz Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Jazz Pharmaceuticals-9.91% 5.02% 1.73% Perrigo -1.86%9.09%3.96% Do analysts prefer JAZZ or PRGO? Jazz Pharmaceuticals presently has a consensus price target of $179.80, indicating a potential upside of 30.34%. Perrigo has a consensus price target of $34.00, indicating a potential upside of 56.97%. Given Perrigo's higher probable upside, analysts clearly believe Perrigo is more favorable than Jazz Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jazz Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.76Perrigo 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 Which has more risk & volatility, JAZZ or PRGO? Jazz Pharmaceuticals has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500. Comparatively, Perrigo has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500. SummaryJazz Pharmaceuticals and Perrigo tied by winning 8 of the 16 factors compared between the two stocks. Get Perrigo News Delivered to You Automatically Sign up to receive the latest news and ratings for PRGO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRGO vs. The Competition Export to ExcelMetricPerrigoMED PRODUCTS IndustryMedical SectorNYSE ExchangeMarket Cap$2.98B$10.99B$6.22B$21.80BDividend Yield5.37%1.88%5.74%3.61%P/E Ratio-37.3320.7728.6532.41Price / Sales0.6927.97550.7684.89Price / Cash4.3025.0537.3824.48Price / Book0.683.4812.314.59Net Income-$171.80M$210.63M$3.33B$1.02B7 Day Performance1.32%-3.25%-1.74%-0.86%1 Month Performance3.86%-1.36%4.72%-0.79%1 Year Performance-16.14%-9.83%61.14%10.17% Perrigo Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRGOPerrigo4.8121 of 5 stars$21.66-1.2%$34.00+57.0%-15.2%$2.98B$4.33B-37.338,379JAZZJazz Pharmaceuticals4.6511 of 5 stars$135.14-0.2%$178.93+32.4%+21.6%$8.22B$4.07B-20.082,800Positive NewsAnalyst ForecastCORTCorcept Therapeutics4.8653 of 5 stars$71.53-3.3%$135.25+89.1%+53.5%$7.79B$675.04M63.30300Upcoming EarningsAnalyst ForecastSUPNSupernus Pharmaceuticals4.0421 of 5 stars$48.38-1.3%$64.00+32.3%+50.5%$2.75B$661.82M42.07580NKTRNektar Therapeutics3.9857 of 5 stars$57.40+5.6%$91.67+59.7%+184.8%$1.03B$98.43M-6.52220PCRXPacira BioSciences4.2343 of 5 stars$22.26-0.4%$33.40+50.0%+27.1%$1.00B$700.97M-8.01720News CoveragePositive NewsOMEROmeros4.3527 of 5 stars$4.19flat$18.00+329.6%+92.0%$285.15MN/A-1.99210ASMBAssembly Biosciences3.4523 of 5 stars$27.66+4.3%$41.25+49.1%+71.2%$203.39M$28.52M-4.96100CPIXCumberland Pharmaceuticals0.6297 of 5 stars$3.36-2.6%N/A+198.4%$51.61M$37.87M-15.2780LLYEli Lilly and Company4.9554 of 5 stars$818.60-1.8%$948.06+15.8%-11.7%$788.86B$45.04B53.5047,000Trending NewsAnalyst ForecastJNJJohnson & Johnson4.8661 of 5 stars$190.88+0.1%$192.94+1.1%+17.9%$459.32B$88.82B20.42138,100Positive NewsAnalyst Upgrade Related Companies and Tools Related Companies Jazz Pharmaceuticals Competitors Corcept Therapeutics Competitors Supernus Pharmaceuticals Competitors Nektar Therapeutics Competitors Pacira BioSciences Competitors Omeros Competitors Assembly Biosciences Competitors Cumberland Pharmaceuticals Competitors Eli Lilly and Company Competitors Johnson & Johnson Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PRGO) was last updated on 10/22/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perrigo Company plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Perrigo With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
